000128768 001__ 128768
000128768 005__ 20240228143347.0
000128768 0247_ $$2doi$$a10.1007/s11060-016-2206-x
000128768 0247_ $$2pmid$$apmid:27422128
000128768 0247_ $$2ISSN$$a0167-594X
000128768 0247_ $$2ISSN$$a0167-594x
000128768 0247_ $$2ISSN$$a1573-7373
000128768 0247_ $$2altmetric$$aaltmetric:9761278
000128768 037__ $$aDKFZ-2017-04783
000128768 041__ $$aeng
000128768 082__ $$a610
000128768 1001_ $$0P:(DE-He78)82e0de3d5aa5330bb2470e74c48773ca$$aHertenstein, Anne$$b0$$eFirst author$$udkfz
000128768 245__ $$aImpact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.
000128768 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2016
000128768 3367_ $$2DRIVER$$aarticle
000128768 3367_ $$2DataCite$$aOutput Types/Journal article
000128768 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524225328_29705
000128768 3367_ $$2BibTeX$$aARTICLE
000128768 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128768 3367_ $$00$$2EndNote$$aJournal Article
000128768 520__ $$aBevacizumab is frequently used in patients with progressive glioblastoma raising questions regarding frequency of treatments, dosage, duration of therapy and the possibility of tapering and discontinuation for selected patient groups. We retrospectively assessed the safety and outcome of tapering and discontinuation of bevacizumab therapy for reasons other than disease progression and toxicity in 19 patients with progressive glioblastoma receiving bevacizumab for at least 6 months. In 10 of the 19 patients tapering bevacizumab resulted in complete discontinuation and reinitiation after disease progression during halted treatment. As a comparison group 33 patients with bevacizumab for at least 6 months continuously dosed at 10 mg/kg every 2 weeks were selected. Age and Karnofsky performance status at start of bevacizumab were similar in both groups. Influenced by the selection process, progression-free survival (PFS) and overall survival (OS) were longer in the group receiving a tapered and discontinued bevacizumab regimen (PFS 22.7 versus 11.2 months, HR 0.33, p-value = 0.01; OS 29.9 versus 15.5 months, HR 0.22, p-value = 0.001) with a median time of discontinuation of 4.5 months (range: 1.9-44.2 months). Stable disease or partial response according to RANO at ≥3 months was achieved in 89 % of patients with reinitiated bevacizumab therapy after discontinuation. These data indicate that tapering and discontinuation of bevacizumab therapy for other reasons than progression is feasible without an increased risk for tumor rebound or unresponsiveness to reinitiated bevacizumab therapy.
000128768 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000128768 588__ $$aDataset connected to CrossRef, PubMed,
000128768 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000128768 7001_ $$0P:(DE-HGF)0$$aMenn, Oliver$$b2
000128768 7001_ $$0P:(DE-He78)2d0c564eca775a62ff86225f7717af12$$aWiestler, Benedikt Paul Otmar$$b3$$udkfz
000128768 7001_ $$0P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aWinkler, Frank$$b4$$udkfz
000128768 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b5$$udkfz
000128768 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b6$$udkfz
000128768 7001_ $$aWick, Antje$$b7
000128768 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-016-2206-x$$gVol. 129, no. 3, p. 533 - 539$$n3$$p533 - 539$$tJournal of neuro-oncology$$v129$$x1573-7373$$y2016
000128768 909CO $$ooai:inrepo02.dkfz.de:128768$$pVDB
000128768 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)82e0de3d5aa5330bb2470e74c48773ca$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128768 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128768 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000128768 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d0c564eca775a62ff86225f7717af12$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000128768 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c294453ee36ad59deddc5494fa6aa4b$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128768 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128768 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000128768 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000128768 9141_ $$y2016
000128768 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000128768 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2015
000128768 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128768 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128768 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128768 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128768 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128768 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128768 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128768 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128768 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128768 9201_ $$0I:(DE-He78)G160-20160331$$kG160$$lNeuroimmunologie und Hirntumorimmunologie$$x0
000128768 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000128768 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x2
000128768 980__ $$ajournal
000128768 980__ $$aVDB
000128768 980__ $$aI:(DE-He78)G160-20160331
000128768 980__ $$aI:(DE-He78)C060-20160331
000128768 980__ $$aI:(DE-He78)G370-20160331
000128768 980__ $$aUNRESTRICTED